The synthesis of three new arginine vasopressin (AVP) analogues with changes at position 1 and 8 is reported. They are: 1-(1-mercapto-4-methylcyclohexaneacetic acid)-8-D-arginine-vasopressin, 1-(4-tert-butyl-1-mercaptocyclohexaneacetic acid)-8-D-arginine-vasopressin and 1-(1-mercapto-4-phenylcyclohexaneacetic acid)-8-D-arginine-vasopressin. They all proved to be potent and selective antagonists of the vasopressor response to AVP. They lacked antagonism in the antidiuretic assay (AD), but retained small agonism in this system. The Arg8 substitution instead of Arg8 in case of the described AVP analogues did not lead to any significant change of antagonistic potency or selectivity.
Download full-text PDF |
Source |
---|
Discov Med
January 2025
Department of Pharmacology "Otto Orsingher", Institute of Experimental Pharmacology of Córdoba (IFEC-CONICET), Faculty of Chemical Sciences, National University of Córdoba, X5000 Córdoba, Argentina.
Background: Angiotensin II, is critical in regulating the sympathetic and neuroendocrine systems through angiotensin II type 1 receptors (AT-R). Angiotensin II intracerebral administration increases water and sodium intake, as well as renal sodium excretion. Previously, our group has shown that AT-R is involved in behavioral and neurochemical sensitization induced by amphetamine.
View Article and Find Full Text PDFCurr Vasc Pharmacol
January 2025
IRCCS San Raffaele Cassino, 03043, Cassino, Italy.
Purpose: The management of acute heart failure (AHF) is crucial and challenging. Regarding the use of inotropes, correct patient selection and time of administration are of the essence. We hypothesize that the early use of Levosimendan favouring hemodynamic stabilization and enables rapid optimization of guideline-directed medical treatment (GDMT) in patients with HF, eventually impacting the patient's prognosis during the vulnerable phase.
View Article and Find Full Text PDFFront Immunol
January 2025
Biotherapy Center and Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Introduction: Malignant pleural effusion (MPE) is associated with poor quality of life and mortality in patients with tumors. In clinical practice, we observed that patients with malignant pleural effusion (MPE) and concurrent heart disease exhibited a decrease in MPE volumes following treatment with β-receptor blockers for heart disease. Immunosuppressive tumor microenvironment was found to play a substantial role in the progression of MPE, and mainly attributed to tumor-associated macrophages (TAMs).
View Article and Find Full Text PDFBackground: Prostaglandin E (PGE) in the rostral ventrolateral medulla (RVLM) has been recognized as a pivotal pressor substance in hypertension, yet understanding of its effects and origins in the RVLM remains largely elusive. This study aimed to elucidate the pivotal enzymes and molecular mechanisms underlying PGE synthesis induced by central Ang II (angiotensin II) and its implications in the heightened oxidative stress and sympathetic outflow in hypertension.
Methods And Results: RVLM microinjections of PGE and Tempol were administered in Wistar-Kyoto rats.
Int J Mol Sci
December 2024
Department of Physiology, Faculty of Medicine, Semmelweis University, 37-47 Tűzoltó Street, 1094 Budapest, Hungary.
The octapeptide angiotensin II (Ang II) is a circulating hormone as well as a locally formed agonist synthesized by the angiotensin-converting enzyme (ACE) of endothelial cells. It forms a powerful mechanism to control the amount and pressure of body fluids. All main effects are directed to save body salt and water and ensure blood pressure under basic conditions and in emergencies.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!